A Phase 2 interventional study of Abiraterone Acetate and Androgen deprivation therapy in Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma in the Soft Tissue, sponsored by ECOG-ACRIN Cancer Research Group. Active, not recruiting at 672 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by ECOG-ACRIN Cancer Research Group · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 28 in phase 2, and was the 36th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Jina Pharmaceuticals Inc.
Ages 18+ · Men only
By country, each count listing its studies:
cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 60 across the 46 interventional studies. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 46 have an industry lead sponsor. The 10 most frequent:
ECOG-ACRIN Cancer Research Group is the lead sponsor of 122 studies on the registry; 16 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
ECOG-ACRIN Cancer Research Group has 9 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing cabazitaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890832Jina Pharmaceuticals Inc.A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | 2026-12 |
| NCT06085729M.D. Anderson Cancer CenterPhase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | 2027-09-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and/or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel and prednisone may help kill more tumor cells.
PRIMARY OBJECTIVES:
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone.
SECONDARY OBJECTIVES:
I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can increase the percentage of change in prostate-specific antigen (PSA) from baseline to week 12 of treatment as well as the maximum decline in PSA that occurs at any point after treatment compared to abiraterone acetate alone.
II. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can prolong time to PSA progression compared to abiraterone acetate alone.
III. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel for HSPC can improve radiographic response (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) compared to abiraterone acetate alone.
IV. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can prolong the overall survival (OS) compared to abiraterone acetate alone.
V. To assess safety and tolerability of the combination of 6 cycles of cabazitaxel and abiraterone acetate.
TERTIARY OBJECTIVES:
I. To examine whether patients with circulating tumor cells (CTCs) positive for AR-V7 at baseline have a longer radiographic or clinical PFS to the combination of cabazitaxel and abiraterone acetate vs. abiraterone acetate alone.
II. To examine whether the addition of cabazitaxel to abiraterone acetate can change the AR-V7 status of patients who are positive at study entry.
III. To examine whether the addition of cabazitaxel to abiraterone acetate has any impact on future development of AR-V7 positivity at the time of disease progression.
IV. To assess if the changes in total tumor burden from baseline to week 12 as assessed with sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) will differ between two arms.
V. To correlate total tumor burden at the baseline as assessed with NaF PET/CT with the PFS.
VI. To correlate heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT with the PFS.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive abiraterone acetate orally (PO) once daily (QD) on days 1-21, prednisone PO twice daily (BID) on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel intravenously (IV) over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either luteinizing hormone-releasing hormone (LHRH) agonist or antagonist, or surgical castration with bilateral orchiectomy.
ARM B: Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
After completion of study treatment, patients are followed up every 3 or 6 months and then annually for up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for PSA, or non-measurable (bone) disease during treatment with ADT:
NaF PET/CT OPTIONAL SUB-STUDY ELIGIBILITY CRITERIA
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
Drug: Abiraterone Acetate · Drug: Androgen deprivation therapy · Drug: Cabazitaxel · Drug: Prednisone
Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
Drug: Abiraterone Acetate · Drug: Androgen deprivation therapy · Drug: Prednisone
Given PO
Also known as: Zytiga
Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist or surgical castration with bilateral orchiectomy.
Given IV
Also known as: Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258
Given PO
Also known as: Deltasone, Orasone, Medicorten, Panasol-S, Liquid-Pred
Progression-free Survival (PFS)
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment.
Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Percent Change in PSA From Baseline to 12 Weeks
PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100
Time frame: Assessed at baseline and 12 weeks
Maximum Percent Change in PSA From Baseline While on Treatment
Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100
Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Time to PSA Progression
Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event.
Time frame: Assessed at baseline, every 3 weeks for 18 weeks, then every 6 weeks until treatment discontinuation, up to 5 years
Proportion of Patients With Radiographic Response
Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Assessed every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Overall Survival (OS)
Overall survival was defined as the time from randomization until death or date last known alive.
Time frame: Assessed every 3 month is patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, and then annually for up to year 5
PFS Among Patients With Circulating Tumor Cells (CTCs) Positive for Androgen-receptor Splice Variant 7 Messenger RNA (AR-V7) at Baseline
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. AR-V7 was assessed at baseline.
Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
Androgen-Receptor Splice Variant 7 Messenger RNA (AR-V7) Status
The presence of AR-V7 in circulating tumor cells was assessed at baseline and Cycle 5 Day 1.
Time frame: Assessed at baseline and Cycle 5 Day 1
Development of AR-V7 Positivity at the Time of Disease Progression
The presence of AR-V7 in circulating tumor cells was assessed at baseline and disease progression.
Time frame: Assessed at baseline and disease progression
Changes in Total Tumor Burden From Baseline to Week 12 as Assessed With NaF PET/CT
Total tumor burden was assessed by NaF PET/CT at baseline and 12 weeks. The changes in total tumor burden will be compared between the two arms.
Time frame: Assessed at baseline and 12 weeks
Association Between PFS and Total Tumor Burden at the Baseline as Assessed With NaF PET/CT
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and total tumor burden at baseline as assessed with NaF PET/CT will be evaluated.
Time frame: Assessed at baseline, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
The Association Between PFS and the Heterogeneity of Response From Baseline to Week 12 as Assessed With NaF PET/CT
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and the heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT will be evaluated.
Time frame: Assessed at baseline, 12 weeks, every 9 weeks for the first 18 weeks, then every 12 weeks until treatment discontinuation; if treatment discontinued prior to radiographic progression, then every 3 months until radiographic progression, up to 5 years
This study was activated on February 8, 2018 and closed to accrual on March 26, 2021, after accrual of 223 patients.
| Milestone | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Started | 111 | 112 |
| Patients who received protocol therapy | 109 | 108 |
| Patients who started protocol therapy and had both baseline psa as well as 12-week psa available | 100 | 93 |
| Completed | 0 | 0 |
| Not completed | 111 | 112 |
| Withdrew: Disease progression | 37 | 36 |
| Withdrew: Adverse event | 6 | 9 |
| Withdrew: Withdrawal by subject | 9 | 7 |
| Withdrew: Death | 5 | 1 |
| Withdrew: Alternative therapy | 4 | 2 |
| Withdrew: Psa progression | 8 | 10 |
| Withdrew: Rising psa and bone issues | 3 | 2 |
| Withdrew: Clinical deterioration/clinical progression/symptomatic progression | 10 | 16 |
| Withdrew: Physician decision | 12 | 11 |
| Withdrew: Second malignancy | 1 | 0 |
| Withdrew: Insurance status change/patient could not afford | 2 | 1 |
| Withdrew: Non-compliance | 1 | 3 |
| Withdrew: Mistakenly off treatment | 1 | 0 |
| Withdrew: Transition to hospice | 1 | 0 |
| Withdrew: Still on treatment | 9 | 8 |
| Withdrew: Never received protocol therapy | 2 | 4 |
| Withdrew: Other complicating disease | 0 | 1 |
| Withdrew: Patient switched from prednisone to another steroid | 0 | 1 |
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment.
| months | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Progression-free Survival (PFS) | 14.9 (9.9 to 18.6) | 9.9 (7.0 to 12.6) |
PSA was assessed at baseline and 12 weeks. Percent change in PSA from baseline to 12 weeks is calculated as follows: ((PSA at 12 weeks - baseline PSA)/baseline PSA) x 100
| percentage of change in PSA | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Percent Change in PSA From Baseline to 12 Weeks | -87.5 (-94.9 to -52.1) | -65.9 (-91.3 to -16.1) |
Maximum percent change in PSA from baseline while on treatment was calculated as follows: ((PSA nadir while on treatment - baseline PSA)/baseline PSA) x 100
| percentage of change in PSA | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Maximum Percent Change in PSA From Baseline While on Treatment | -94.0 (-98.1 to -65.8) | -67.7 (-94.8 to -15.5) |
Time to PSA progression was defined as the time from randomization to PSA progression or date of last PSA assessment. Patients who experienced radiographic progression without documented PSA progression were counted as having an event.
| months | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Time to PSA Progression | 10.0 (8.5 to 13.5) | 6.1 (4.4 to 8.0) |
Radiographic response was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and was defined as either complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. All (non-target) lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Proportion of participants | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Proportion of Patients With Radiographic Response | 0.117 (0.064 to 0.192) | 0.080 (0.037 to 0.147) |
Overall survival was defined as the time from randomization until death or date last known alive.
| months | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| Overall Survival (OS) | 25.0 (20.6 to 32.5) | 26.9 (19.6 to 29.4) |
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. AR-V7 was assessed at baseline.
Results for this outcome have not been posted.
The presence of AR-V7 in circulating tumor cells was assessed at baseline and Cycle 5 Day 1.
Results for this outcome have not been posted.
The presence of AR-V7 in circulating tumor cells was assessed at baseline and disease progression.
Results for this outcome have not been posted.
Total tumor burden was assessed by NaF PET/CT at baseline and 12 weeks. The changes in total tumor burden will be compared between the two arms.
Results for this outcome have not been posted.
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and total tumor burden at baseline as assessed with NaF PET/CT will be evaluated.
Results for this outcome have not been posted.
PFS is defined as time from randomization to radiographic progression, symptomatic deterioration requiring discontinuation of treatment or death, whichever occurs first. Patients who died without documented radiographic progression or symptomatic deterioration and the death occurred more than 6.5 months after the date of last disease assessment were censored at the date of last disease assessment. The association between PFS and the heterogeneity of response from baseline to week 12 as assessed with NaF PET/CT will be evaluated.
Results for this outcome have not been posted.
Collected over Assessed every 3 weeks while on treatment and for 30 days after the end of treatment, up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | 80/111 (72.1%) | 46/109 (42.2%) | 101/109 (92.7%) |
| Arm B (Abiraterone Acetate, Prednisone) | 79/112 (70.5%) | 31/108 (28.7%) | 80/108 (74.1%) |
| Event | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| HypertensionVascular disorders | 11/109 | 12/108 |
| Neutrophil count decreasedInvestigations | 11/109 | 0/108 |
| White blood cell decreasedInvestigations | 9/109 | 0/108 |
| AnemiaBlood and lymphatic system disorders | 7/109 | 1/108 |
| FatigueGeneral disorders and administration site conditions | 6/109 | 2/108 |
| Alanine aminotransferase increasedInvestigations | 1/109 | 5/108 |
| Urinary tract infectionInfections and infestations | 5/109 | 0/108 |
| HypokalemiaMetabolism and nutrition disorders | 4/109 | 4/108 |
| DiarrheaGastrointestinal disorders | 4/109 | 0/108 |
| SepsisInfections and infestations | 4/109 | 0/108 |
| Event | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) |
|---|---|---|
| FatigueGeneral disorders and administration site conditions | 78/109 | 47/108 |
| AnemiaBlood and lymphatic system disorders | 60/109 | 30/108 |
| DiarrheaGastrointestinal disorders | 37/109 | 6/108 |
| HypertensionVascular disorders | 37/109 | 36/108 |
| Edema limbsGeneral disorders and administration site conditions | 22/109 | 13/108 |
| HypokalemiaMetabolism and nutrition disorders | 19/109 | 19/108 |
| VomitingGastrointestinal disorders | 18/109 | 4/108 |
| Lymphocyte count decreasedInvestigations | 14/109 | 3/108 |
| ConstipationGastrointestinal disorders | 12/109 | 8/108 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 12/109 | 9/108 |
All randomized patients were included in this analysis.
| Age, Continuous(years) | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) | Total |
|---|---|---|---|
| Median | 63 (42 to 79) | 66 (41 to 80) | 64 (41 to 80) |
| Sex: Female, Male(Participants) | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 111 | 112 | 223 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 104 | 105 | 209 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel) | Arm B (Abiraterone Acetate, Prednisone) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 22 | 42 |
| White | 84 | 81 | 165 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 5 | 12 |
Showing the first 100 of 672 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Ran from Apr 2018 to primary completion in Jan 2024, 68 months.
Results were first posted in Jan 2026, 2 years after primary completion.
Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's 68 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabazitaxel
ECOG-ACRIN Cancer Research Group →